Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Maze Therapeutics, Inc. (MAZE) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $24,03, with a market capitalisation of $1,37B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22,45 to $53,65. This page covers its latest market performance, valuation, price trends and company information.
$1,37B | |
$24,33 | |
$53,65 | |
$6,71 | |
$24,23 | |
40,96K | |
551,79K | |
-- | |
$53,65 | |
$22,45 | |
-- | |
-- |
Maze Therapeutics, Inc. (MAZE) is currently trading at $24,03 as of 2026-09-16 14:24:42, down 0,85% ($0,21) from the previous close of $24,23
During today's regular trading session, MAZE has traded between $6,71 and $53,65, with a trading volume of 40,96K shares. The current price is near the middle of today's range.
Over the past seven days, Maze Therapeutics, Inc. (MAZE) moved from $26,21 to $24,03, representing a decline of 8,34% ($2,19).
The stock traded between $23,69 and $26,57 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 614,32 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5,1%
MAZE is currently trading at $24,03, placing it 5,1% of the way from its 52-week low of $22,45 to its 52-week high of $53,65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 141 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Maze Therapeutics, Inc. (MAZE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.